Navigation Links
Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
Date:8/30/2007

A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

In a series of laboratory and animal experiments, Johns Hopkins scientists blocked the signaling system, known as Hedgehog, with an experimental compound called cyclopamine to explore the blockades effect on cancer stem cells that populate glioblastoma multiforme. Cyclopamine has long been known to inhibit Hedgehog signaling.

They reported their findings in the journal Stem Cells published online on July 19.

Our study lends evidence to the idea that the lack of effective therapies for glioblastoma may be due to the survival of a rare population of cancer stem cells that appear immune to conventional radiation and chemotherapy, says Charles G. Eberhart, M.D., Ph.D., associate professor of pathology, ophthalmology and oncology, who led the work. Hedgehog inhibition kills these cancer stem cells and prevents cancer from growing and may thus develop into the first stem cell-directed therapy for glioblastoma.

Eberhart cautioned that while his study appears to prove the principle of Hedgehog blocking, much work remains before cyclopamine or any similar drug can be tested in patients. Scientists must determine whether the drug can be effectively and safely delivered to the whole body or whether it must go into the brain, and what if any adverse impact on normal stem cells the treatment might cause.

Once youve answered those questions in animals, the next step would be starting phase I clinical trials in humans, Eberhart said.

The new study adds to the growing evidence that only a small percentage of cancer cells - in this case stem cells - are capable of unlimited self-renewal and that these cells alone power a tumors growth.

Eberhart focused
'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. Experimental drug to fight flu
3. Experimental SARS Vaccine
4. Experimental vaccine for shingles is effective
5. Experimental Blood Test May Spot Heart Attack Risk, Study Says
6. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
7. TMC 114 and 125 experimental drugs to be tested on four HIV patients
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Researchers at Barrow Neurological Institute at St. Joseph,s ... why the public perceives some magic tricks in ... military tactics, marketing and sports. , Susana Martinez-Conde, ... Stephen Macknik, PhD, of Barrow,s Laboratory of Behavioral ... magic and illusions. Their most recent original research ...
(Date:5/22/2012)... 22, 2012) Scientists at Virginia Commonwealth University ... to developing a new therapy for acute myeloid ... obatoclax and sorafenib kill leukemia cells much more ... administered individually., Recently published in the journal Blood, ... Grant, M.D., Shirley Carter Olsson and Sture Gordon ...
(Date:5/22/2012)... to stray from her breeding partner and mate with ... that sleeping around can be costly. , The 20-year ... found that offspring conceived outside sparrows, social pairs ... offspring. The findings throw a monkey wrench into theories ... cheat. , Most bird species display some form of ...
(Date:5/22/2012)... Medical College of Wisconsin have identified novel biomarkers that ... in large groups of people potentially exposed to unknown ... treatment. , The findings are published in the May ... E. Baker, Ph.D., professor of surgery, biochemistry, pharmacology and ... lead author of the study. , There is an ...
(Date:5/22/2012)... May 22 (HealthDay News) -- Body-building and weight-loss products ... cause liver injury, according to a small new study. ... drugs are taken off the market. Dietary and herbal ... can be bought over the counter or online -- ... in the United States, but their potential side effects ...
Breaking Medicine News(10 mins):Health News:Barrow researchers use magic for discoveries 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 3Health News:For monogamous sparrows, it doesn't pay to stray (but they do it anyway) 2Health News:Body Building, Diet Supplements Linked to Liver Damage: Study 2
... COPD Population Will Rise by Nearly 19 Percent as a Result ... from Decision ... Resources, ... leading research and advisory firms for pharmaceutical and,healthcare issues, finds that ...
... shelter for virus out of reach of drugs , , ... a certain type of cell provides a "hideout" for HIV ... humans. , These follicular dendritic cells (FDCs) are located throughout ... researchers at Brigham Young University and Johns Hopkins School of ...
... healthcare system better understand where to focus ... it offers, CAMBRIDGE, MA, May 28 /PRNewswire/ ... and safety software that helps organizations manage,infection control ... medical incidents, claims and quality issues,announced today that ...
... Glycoproducts International,Inc., a provider of nutritional supplement ... sitting in the Northern District of Texas ... Glycoproducts International, Inc.,committed patent infringement of two ... Mannatech,s AMBROTOSE(R) technology., The jury ruled ...
... ANGELES, May 28 5-year-old Noor came to,the attention ... 1st,Battalion, 30th Infantry Regiment, 2nd Brigade Combat Team through ... resulted,in the death of the little girl,s uncle. The ... surgeon, concluded that Noor is blind,due to a birth ...
... standards and the life style connected to them seem ... symptoms. This has lead to the assumption that the ... structures or to exogenous non-infectious proteins, i.e. allergens, when ... protect the individual from infections. , The European ...
Other Medicine News:Health News:Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017 2Health News:Scientists Break Into HIV 'Hideout' 2Health News:Caritas Christi Standardizes on rL Solutions to Help Deliver Best in Class Healthcare Quality 2Health News:Jury Rules in Favor of Glycoproducts International, Inc. 2Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2Health News:Researchers from 5 countries to test hygiene hypothesis with EU funding 2
(Date:5/22/2012)... Serbia, May 22, 2012 Sorbent Therapeutics, ... and renal diseases, presented positive data from its ... study of 111 heart failure patients with chronic ... symptoms as compared to placebo.    ... were presented in an oral session at the ...
(Date:5/22/2012)... -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based ... Human Immunodeficiency Virus (HIV) infections, today announced that ... opened enrollment for a Phase 1 trial for ... is identical to the first generation ... for the inclusion of granulocyte-macrophage colony-stimulating factor (GM-CSF) ...
(Date:5/22/2012)...   USANA Health Sciences , Inc. (NYSE: ... announced the promotion of Dr. John Cuomo to executive ... Dixon to executive director of new product and technological ... Mark Levy, a Ph.D. in human nutrition, and John ... professor at the University of Utah, have joined USANA,s ...
Breaking Medicine Technology:Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 2HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 3HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 4USANA Health Sciences Expands Award-Winning Research and Development Team 2USANA Health Sciences Expands Award-Winning Research and Development Team 3Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution 20047 1Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution 20047 2Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution 20047 3Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution 20047 4PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes 20044 1PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes 20044 2Debiopharm and Ascenta Therapeutics Inc Announce An Exclusive License Agreement for the Development and Commercialization of the IAP 28Inhibitor of 20439 1Debiopharm and Ascenta Therapeutics Inc Announce An Exclusive License Agreement for the Development and Commercialization of the IAP 28Inhibitor of 20439 2Debiopharm and Ascenta Therapeutics Inc Announce An Exclusive License Agreement for the Development and Commercialization of the IAP 28Inhibitor of 20439 3
... week ARTEMIS data presented at ICAAC -, ... today from a phase 3, randomized, open-label, ongoing ... infected adults,taking PREZISTA(R) 800 mg (two 400 mg ... an undetectable viral load (<50 copies/mL) at week ...
... Phase III studies affirmed the clinical benefits of,ACTEMRA ... from two Phase III studies,showed that patients who ... arthritis (RA) achieved significant improvements in signs and,symptoms ... combination,with methotrexate compared with methotrexate alone. The final ...
Other Medicine Technology:Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 2Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 3Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 4Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 5Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 6Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 8ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: